Alspach, Elise
Lussier, Danielle M.
Miceli, Alexander P.
Kizhvatov, Ilya
DuPage, Michel
Luoma, Adrienne M.
Meng, Wei
Lichti, Cheryl F.
Esaulova, Ekaterina
Vomund, Anthony N.
Runci, Daniele
Ward, Jeffrey P.
Gubin, Matthew M.
Medrano, Ruan F. V.
Arthur, Cora D.
White, J. Michael
Sheehan, Kathleen C. F.
Chen, Alex
Wucherpfennig, Kai W.
Jacks, Tyler
Unanue, Emil R.
Artyomov, Maxim N.
Schreiber, Robert D.
Article History
Received: 13 February 2019
Accepted: 12 September 2019
First Online: 23 October 2019
Competing interests
: R.D.S. is a cofounder, scientific advisory board member, stockholder, and royalty recipient of Jounce Therapeutics and Neon Therapeutics and is a scientific advisory board member for A2 Biotherapeutics, BioLegend, Codiak Biosciences, Constellation Pharmaceuticals, NGM Biopharmaceuticals and Sensei Biotherapeutics. K.W.W. serves on the scientific advisory board of Tscan Therapeutics and Nextechinvest, and receives sponsored research funding from Bristol-Myers Squibb and Novartis; these activities are not related to the findings described in this publication. T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific. He is also a co-founder of Dragonfly Therapeutics and T2 Biosystems, and serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech, and Skyhawk Therapeutics. None of these affiliations represent a conflict of interest with respect to the design or execution of this study or interpretation of data presented in this manuscript. The laboratory of T.J. currently also receives funding from the Johnson & Johnson Lung Cancer Initiative and Calico, but this funding did not support the research described in this manuscript.